Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Sands, Bruce; Peyrin-Biroulet, Laurent; Loftus, Edward; Danese, Silvio; Colombel, Jean-Frederic; TÖRÜNER, MURAT; Jonaitis, Laimas; Abhyankar, Brihad; Chen, Jingjing; Rogers, Raquel; Lirio, Richard; Bornstein, Jeffrey; Schreiber, Stefan

doi:10.1056/nejmoa1905725

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Copy For Citation

Sands B. E., Peyrin-Biroulet L., Loftus E. V., Danese S., Colombel J., TÖRÜNER M., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.381, no.13, pp.1215-1226, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 381 Issue: 13
Publication Date: 2019
Doi Number: 10.1056/nejmoa1905725
Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1215-1226
Ankara University Affiliated: Yes

Abstract

BackgroundBiologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking.